Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Epilepsy |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 12 - 55 |
| Updated: | 4/21/2016 |
| Start Date: | September 2009 |
| End Date: | March 2010 |
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both
children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.
children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.
Inclusion Criteria:
- Subjects with a diagnosis of epilepsy on up to three concomitant anti-epileptic drugs
- Subjects on levetiracetam immediate release (IR) can be enrolled if on a stable dose
for 7 days
Exclusion Criteria:
- Subjects with a history of status epilepticus within 3 months of Visit 1
- Subject has difficult venous accessibility
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials